Krakoff I H, Cvitkovic E, Currie V, Yeh S, LaMonte C
Cancer. 1977 Nov;40(5):2027-37. doi: 10.1002/1097-0142(197711)40:5<2027::aid-cncr2820400506>3.0.co;2-a.
The clinical toxicology, clinical pharmacology, and therapeutic effects of bleomycin given by continuous intravenous infusion were studied in patients with far-advanced unresectable cancer. The toxicity of bleomycin given by that schedule was qualitatively and quantitatively the same as when it was given by daily intravenous "push"; mucocutaneous toxicity occurred regularly after 7-11 days of infusion. Careful monitoring of pulmonary function revealed minor changes in Total Lung Capacity and Pulmonary Diffusion Capacity in nearly all patients; however, overt pulmonary toxicity occurred in only six patients (5%). 111Indium-labeled bleomycin was used to follow blood levels of bleomycin; it correlated well with the levels determined by microbiologic assay and could be measured at levels lower than could be determined by bioassay. Useful therapeutic responses were seen in a variety of tumors; 30% patients with very far-advanced carcinoma of the cervix demonstrated CR or PR, an incidence higher than has been seen with other regimens. Sixty-nine percent of patients with disseminated germ cell neoplasms of the testis, refractory to bleomycin given by conventional dose schedules, have attained partial remission through the continuous infusion of bleomycin.
对晚期无法切除的癌症患者研究了持续静脉输注博来霉素的临床毒理学、临床药理学及治疗效果。按此给药方案给予博来霉素时，其毒性在性质和数量上与每日静脉“推注”给药时相同；在输注7 - 11天后经常出现皮肤黏膜毒性。对肺功能的仔细监测显示，几乎所有患者的肺总量和肺弥散容量都有轻微变化；然而，仅6例患者（5%）出现明显的肺部毒性。使用铟 - 111标记的博来霉素来跟踪博来霉素的血药浓度；它与微生物测定法测定的浓度相关性良好，且能在低于生物测定法可测定的浓度水平进行测量。在多种肿瘤中都观察到了有效的治疗反应；30%的晚期宫颈癌患者出现完全缓解或部分缓解，这一发生率高于其他治疗方案。69%对传统给药方案的博来霉素治疗无效的播散性睾丸生殖细胞瘤患者，通过持续输注博来霉素获得了部分缓解。
